Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells
BackgroundChemotherapy resistance is the major cause of failure in neuroblastoma (NB) treatment. ATXN3 has been linked to various types of cancer and neurodegenerative diseases; however, its roles in NB have not been established. The aim of our study was to explore the role of ATXN3 in the cell deat...
Main Authors: | Baocheng Gong, Jinhua Zhang, Zhongyan Hua, Zhihui Liu, Carol J. Thiele, Zhijie Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.686898/full |
Similar Items
-
Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
by: Baocheng Gong, et al.
Published: (2022-08-01) -
The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
by: Hai-Ling Gao, et al.
Published: (2023-07-01) -
Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
by: Anna Richter, et al.
Published: (2021-03-01) -
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
by: Elizabeth H. Stover, et al.
Published: (2022-04-01) -
MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro
by: Meiling Chen, et al.
Published: (2022-11-01)